T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

• Status: Withdrawn
• Trial end date: 2019-10-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center cross-sectional imaging study in patients with localized lung cancer undergoing immunotherapy with or without stereotactic radiation therapy as part of the companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer). Each patient will undergo a single [18F]F-AraG PET exam as part of this study. [18F]F-AraG will be administered at a single time point intravenously prior to PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT) used for attenuation correction and anatomic localization of [18F]F-AraG uptake, SUV calculation, and volumetric selection for radiomic analyses.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: CellSight Technologies, Inc.
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

1. Age greater than or equal to 18 years

2. Histologically or cytologically documented stage I-IIIA non-small cell lung cancer (NSCLC)

3. Eligible for with plan to undergo immunotherapy alone or both immunotherapy and stereotactic radiation therapy as part of NCT03217071

4. In female patients, negative pregnancy test with no plans to become pregnant during the duration of the study

5. Able to provide informed consent and follow the study guidelines

Exclusion Criteria:

1. Female patients who are pregnant or breastfeeding